

# Quanterix™

## Quanterix Chairman and CEO Kevin Hrusovsky to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference and Appear on the June 3 Episode of The Bio Report

June 2, 2021

BILLERICA, Mass.--(BUSINESS WIRE)--Jun. 2, 2021-- [Quanterix Corporation](https://www.quanterix.com/) (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that Chairman and Chief Executive Officer, Quanterix, Kevin Hrusovsky will be delivering a virtual presentation at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10<sup>th</sup> at 3:50pm ET.

Attendees can access the public webcast at <https://kygo.com/gs-global-healthcare/quanterix-june-2021> or by visiting the News & Events page within the Investors section of the Quanterix website at <http://www.quanterix.com/>. Replays of the webcast will be available on the Quanterix website for 90 days following the conference.

Additionally, Hrusovsky will appear on the June 3 episode of [The Bio Report](http://thebioreport.com/), a leading podcast that focuses on the intersection of biotechnology and business, science, and policy. The episode, which airs at 4:00 p.m., EDT, will be available to listen on demand at <http://thebioreport.com/> or through the following podcast providers: Apple Podcasts, iHeart Radio, Google Podcasts, Soundcloud, and Stitcher.

### To learn more about Quanterix, visit:

<https://www.quanterix.com/>

### About Quanterix

Quanterix is a company that's digitizing biomarker analysis with the goal of advancing the science of precision health. The company's digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix' technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit <https://www.quanterix.com>.

### Forward-Looking Statements

*This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix' expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix' actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix' filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.*

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210602005758/en/): <https://www.businesswire.com/news/home/20210602005758/en/>

### Media Contacts:

PAN Communications  
Staci Didner, 617-502-4300  
[quanterix@pancomm.com](mailto:quanterix@pancomm.com)

### Investor Relations Contact:

Stephen Hrusovsky  
(774) 278-0496  
[shrusovsky@quanterix.com](mailto:shrusovsky@quanterix.com)

Source: Quanterix Corporation